Merck KGaA (MRK) Earnings Call Transcript & Summary

November 11, 2021

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 61 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and thank you for joining the Merck Investor and Analyst Conference Call covering the third quarter of 2021. Just a quick note that everyone attending will remain in listen-only mode for the session. At this point, I’ll pass things over to Mr. Constantin Fest, our Head of Investor Relations, who will guide you through today’s conference. Mr. Fest, the floor is yours.

Constantin Fest

executive
#2

Thanks, Tracy. A very warm welcome, ladies and gentlemen, to this call on our Q3 2021 results. I’m Constantin Fest, Head of Investor Relations at Merck. I’m very pleased to be joined today by Belén Garijo, our Group CEO, and Marcus Kuhnert, Group CFO. Also with us for today’s Q&A are Matthias Heinzel, CEO of Life Science, Peter Guenter, CEO of Healthcare, and Kai Beckmann, CEO of Electronics. Over the next few minutes, we’d like to take you through the presentation’s key slides, and after that we’ll go straight into the Q&A. With that said, I’ll now pass things to Belén for the presentation. Belén, over to you.

Belén Garijo

executive
#3

Thank you, Constantin, and hello everyone from me as well on our Q3 earnings call. I'm turning to Slide 5 now and will begin with the highlights. All in all, Q3 was yet another robust quarter, driven by considerable expansion of Big 3. Life Science posted another record quarter, with Process Solutions in the lead. Bavencio came in above consensus, and Mavenclad sits right at consensus once we adjust for a minor one-time effect that we'll address later. And Semiconductor Solutions turned in solid debit growth during the quarter. On an organic basis, Group sales were up 11%, and EBITDA pre climbed 13% on an underlying basis. That figure excludes the Biogen provision reversal we carried out in Q3 of last year. Currency became a modest tailwind, producing reported sales of €4.97 billion and EBITDA pre of €1.55 billion. Taking a step back to the strategic view. During our Capital Markets Day in September, we had the chance to walk all of you through our plans and priorities for the coming years. There, we underscored our ambition to speed up our science and technology leadership and to drive efficient growth via targeted and highly disciplined investment. Our investment focus will center on the Big 3. And as a quick reminder, we're aiming to reach roughly €25 billion in revenues by 2025.

Belén Garijo

executive
#4

Q3 showed really encouraging momentum, and given how strongly we performed, we're lifting our 2021 outlook once more. Net sales are now projected at €19.3 billion to €19.85 billion. EBITDA pre is expected between €6 billion and €6.3 billion, while EPS pre should land in the €8.5 to €9% range, and we'll walk through the underlying assumptions in more detail later on. Turning to Slide Number 6, I'll give you some extra color on how each business sector performed in a strong Q3. As I said earlier, all three business sectors helped deliver very solid organic growth during Q3. Life Science was the fastest grower, with sales rising almost 18% organically, then Electronics at 10.3% growth and Healthcare at 4.1%. For Q3, currency became a modest tailwind affecting both revenues and EBITDA pre, and that held true across all three business sectors. Now let's dig into the sectors, beginning with Life Science. Keep in mind that results were broad-based, with meaningful contributions from COVID-related business as well as a solid showing from the core business. Every region posted double-digit organic growth, and all customer segments contributed positively. On the portfolio side, Process Solutions continues to be the primary growth engine, with organics up 28%.

Belén Garijo

executive
#5

Research and Applied likewise delivered a strong result, posting organic sales growth in the high single digits. We keep moving forward on raising output in bottleneck areas, and we have lately disclosed a number of significant milestones regarding the acceleration of our CDMO work in novel modalities. Now on to Healthcare. The combined sales of our new launches — Mavenclad, Bavencio and tepotinib — reached more than €300 million, an organic increase of over 60%, which shows real strong momentum. The Fertility franchise, Erbitux and a substantial portion of our CM&E portfolio likewise kept expanding, though this was partly offset — or more than offset, I should say — by the well anticipated declines of Rebif and the temporary effects of China VBP on Glucophage. Within Electronics, double-digit organic growth was chiefly powered by Semiconductor Solutions, which produced 22% higher sales amid positive trends in both semi materials and DS&S. Continued declines in Display Solutions were to a great extent offset by additional business recovery in Surface Solutions. On earnings, EBITDA pre reached €1.5 billion, yielding a strong margin on sales of 31.2%. If you exclude the Biogen provision reversal, which lifted earnings in Q3 2020, EBITDA pre rose 13% organically, and it grew faster than sales thanks to a positive mix, strong operating leverage and, last but not least, rigorous cost discipline.

Belén Garijo

executive
#6

Turning to the following slide. Here you can see how sales break down and how each region grew. Of our three biggest regions, Europe posted the fastest expansion this quarter, with sales rising 16% organically, while North America and Asia Pacific followed, each at 9% organic growth. In Life Science and Electronics, organic growth reached double digits across every major region, and Healthcare recorded double-digit growth in Europe and Asia Pacific. I want to stress that this robust performance from the Big 3 was backed by every major region, which shows the global potential they hold. The slide also shows that our geographic mix stays well balanced: Asia Pacific accounts for 36% of Group sales, Europe 29%, and North America 27%. With that, I'll pass things to Marcus, who will walk you through our financial performance in more detail, and then I'll return for the guidance. Thank you.

Marcus Kuhnert

executive
#7

Thanks very much, Belén, and a warm welcome from me as well. I'm now on Slide Number 9 of the presentation, where I'll give an overview of our key figures for the third quarter. All in all, we're highly satisfied with how we performed in Q3, which showed strong growth along with a nicely leveraged P&L in underlying terms. On a reported basis — that includes modest FX tailwinds — Group net sales rose by 11.8% to €4.97 billion. EBITDA pre fell by 8.7% to €1.55 billion. EPS pre was 4.3% lower at €2.24. Please bear in mind that EBITDA pre for last year got a significant boost of €365 million. That equates to a €0.63 EPS-free contribution stemming from the reversal of a provision tied to the patent dispute overridden — the so-called Biogen provision. If you exclude that effect, EBITDA pre grew 15.2%, which implies an underlying margin expansion of 120 basis points, while EPS pre rose by 31%, helped further by improved financial results and a lower effective tax rate. Please also note that ending the alliance with GSK had a slightly negative impact on our P&L in Q3. We recognized the remaining upfront payment of about €75 million in the third quarter. Of that, roughly €50 million was accelerated because of the termination, which was more than offset by an accrual for outstanding development costs related to the winding down of various studies, and this came to about €70 million.

Marcus Kuhnert

executive
#8

Having said that, operating cash flow came in strong, rising 25% to €1.5 billion, which reflects substantial growth in underlying earnings together with solid management of working capital. Versus the close of Q2, net debt dropped by more than €800 million even with higher CapEx and spending on intangible assets, and net debt to EBITDA continued to improve sequentially, moving from a multiplier of 1.7 to 1.6 now. So let's turn to Slide 10 for some remarks on the earnings figures we reported. Although EBITDA pre fell €149 million year-on-year, EBIT was down €119 million. On an underlying basis — that is, excluding the Biogen provision reversal — EBITDA pre rose by €246 million and EBIT by €260 million, a gain of 31% year-on-year. The percentage rise in underlying EBIT was larger than that of underlying EBITDA pre, owing to lower adjustments this year. The financial result improved markedly thanks to positive effects from deleveraging, and therefore lower interest expense as well as lower LTIP provisions. For the quarter, the effective tax rate stood at 23.1%, entirely consistent with the new guidance range for 2021 that we introduced in May to reflect a more favorable country mix tied in turn to the very strong performance of Life Science. Consequently, reported net income came to €761 million in Q3, and reported EPS was €1.75.

Marcus Kuhnert

executive
#9

Now let's turn to a closer look by business sector, beginning with Life Science on Slide Number 11. Life Science posted yet another all-time high for sales, reaching €2.25 billion in Q3, which was up 17.1% organically. In this segment, the core business and COVID-related sales contributed roughly equally, at around 8% and 9%, respectively. The slower growth versus Q2, though, came as no surprise, since both core and COVID faced tougher comps. Looking at the portfolio, Process Solutions stayed the primary growth driver, with sales rising 28% organically. There, roughly two-third of that growth was tied to COVID and a bit more than one-third to the core. In fact, growth was broad based across every business line, with bioprocessing leading the way. Importantly, sales keep climbing sequentially, thanks to additional productivity gains and the successful ramp-up of new capacities in Denver for single-use and Jeffrey for filtration. Please also note that order intake was robust, still outpacing sales with growth of over 30%. Moving to Research Solutions. Organic growth was a very healthy 7%. That was mainly fueled by continued strength in the core business against rising comps. The COVID-related contribution to growth was comparatively modest, at just plus 1%.

Marcus Kuhnert

executive
#10

Actually, as we had anticipated, COVID-related revenue in Research Solutions came in lower than Q2 and ought to keep declining going forward. Applied Solutions posted organic sales growth of 8%, which came entirely from the unidentified rebound of the core business. As a quick reminder, COVID-related sales in Applied are minimal. Turning to customer segments, Pharma and Biotech performed best, with industrial and testing next, and both of those grew at double-digit rates. The agnostics grew at a high single-digit rate and academia at a low single-digit rate. From a geographic standpoint, we recorded double-digit organic growth across every region. On earnings, EBITDA pre increased 29% organically, with the margin rising 360 basis points to 36.6%. The main drivers were a favorable product mix, which included a larger proportion of COVID-related sales, along with beneficial pricing and operating leverage. Relative to Q2, the margin slipped a little, which mirrors growth investments and substantial headway on hiring to expand capacity. With that said, let's move on to Healthcare on Slide Number 12. On the whole, Healthcare turned in a solid performance in the third quarter. Organic sales rose 4.1%, as a moderate decrease in the established portfolio was more than offset by growth of over 60% in new product sales. Within the franchises, oncology climbed 26% organically, fueled by continued robust uptake of Bavencio in first-line bladder, where sales grew 2.5 times to more than €100 million in Q3, and also by healthy organic growth of 6% for Erbitux.

Marcus Kuhnert

executive
#11

Just to flag, Erbitux sales contained no contribution from that temporary supply arrangement with Eli Lilly, so we now anticipate the remaining €10 million benefit to come through over the next few months. Within our (Ph) franchise, organic growth was modest at 1%, since Rebif declines matching the interferon market were more than made up for by Mavenclad's strong performance, which rose 33% organically, even with the recent COVID-19 wave dampening things amid the dynamic market recovery. Our Fertility business posted robust organic growth of 7%, helped by healthy underlying market dynamics plus catch-up effects from last year. Finally, sales in our CME franchise fell 3.4%, as volume-based procurement pressure on Glucophage in China could not be offset by solid growth across other regions and products. On the pipeline side, let me point out that we recently announced completion of Phase III recruitment for our blockbuster candidate evobrutinib, a BTK inhibitor, and we still expect data in-house by the first quarter of 2023. For a full review of our pipeline, we invite you to join our R&D leadership at the R&D Update Call on November 22nd. Returning to Q3 and moving on with earnings: EBITDA pre fell 42% organically.

Marcus Kuhnert

executive
#12

But as I mentioned before, that came from last year’s reversal of the Biogen provision. If you strip that out, underlying EBITDA pre was roughly flat, with a healthy 30.3% margin—down somewhat versus a year earlier on an underlying basis, because of R&D phasing and the effects of the GSA determination that I described earlier. On non-recurring income, note that in addition to the €75 million upfront recognition, we recorded a high single-digit euro million amount from active portfolio management in Q3. For the full year, we’re revising our non-recurring income guidance to capture the larger upfront recognition from GSK, with every other element left as is. Specifically, we now expect roughly €125 million from GSK rather than the about €100 million previously indicated, about €50 million in milestones for Bavencio—already booked in Q1—and a low to mid-double-digit million euro amount from active portfolio management. Bear in mind that the GSK Bavencio components are fully realized, and active portfolio management income is already well within its target corridor at €30 million after the first nine months. So no meaningful non-recurring income should be anticipated in Q4. Moving to Electronics on Slide 13: all in all, Electronics delivered yet another very strong quarter.

Marcus Kuhnert

executive
#13

On an organic basis, sales rose 10.3% to a record €937 million. So growth was comparable to and already very strong in Q2, even though the drivers differed. Specifically, we saw additional acceleration in Semiconductor Solutions, offset by softer momentum in Display and Surface Solutions plus the tough comparisons. Looking more closely at the business units, beginning with our primary growth engine, Semiconductor Solutions: here sales climbed a remarkable 21% organically, which is well above our upgraded midterm ambition of 7% to 10%. The biggest absolute contributor inside Semiconductor Solutions was our materials business, which delivered double-digit growth on continued strong underlying demand. We also benefited from favorable project phasing in DS&S, which we expect to carry on in Q4 and through the end of next year as well. Sales in Display Solutions declined 7% organically, reflecting the ongoing liquid crystal trends and partly offset by strong double-digit growth in the period. Finally, Surface Solutions achieved organic sales growth of 10%, driven mainly by a strong recovery in the cosmetics business. On earnings, EBITDA pre reached €297 million, up 11% organically, producing a margin of 31.7%. That 130 basis points of margin improvement was supported by sales growth, continued realization of synergies and further rigorous cost management underpinned by the Bright Future initiative.

Marcus Kuhnert

executive
#14

Moving to Slide 14, I'll make a few comments about the balance sheet as of the end of September. The €2 billion increase versus the end of last year stems primarily from strong business growth and currency effects. Cash and cash equivalents rose thanks to strong operating cash flow. Financial debt fell by more than €1 billion, reflecting significant net repayments. Goodwill went up largely because of foreign currencies, and net working capital rose on higher sales. Consequently, our equity ratio climbed from 41% to 47% during the first nine-months of the year, while the net debt-to-EBITDA pre ratio improved from 2.3 times to 1.6 times. Now let's take a closer look at cash flow on Slide 15. Operating cash flow was strong at €1.5 billion, rising 25% year-on-year. The main drivers were a significant lift in underlying earnings along with sound working capital management. Cash-out for investing activities was lower, however, largely because of temporary investment of excess cash in the third quarter of last year. In fact, CapEx rose 24% year-on-year to €295 million, consistent with our full-year guidance and reflecting ongoing capacity expansions that support the strong growth of key businesses.

Marcus Kuhnert

executive
#15

And lastly, the notable rise in cash paid out for financing activities is clearly attributable to the additional repayments of bank liabilities and commercial paper that I mentioned. So with that said, I'll turn things back over to Belén for the outlook.

Belén Garijo

executive
#16

Thank you, Marcus. Before we get into the full-year guidance, I'd like to give you a wider perspective on inflationary and supply chain pressures, because this has been a topic for (Ph) some of you, and we've gotten a number of questions about it. So our view is clear. We believe we're well positioned to manage profitability amid higher input volatility. First of all, gross margins are generally attractive, as you can see on the slide, which gives us a solid starting point. We have the highest gross margin in Healthcare, and while pricing flexibility is lower compared with the other sectors, manufacturing costs are lower as well, and our exposure to critical raw materials is limited. Beyond that, for Healthcare, the share of discretionary spend is higher, which provides greater flexibility on cost management, as we have done to-date. In Life Science, gross margins are also very healthy, and we are closely monitoring inflation and potential effects on labor costs in some countries, selected raw materials and construction services. The good news is that material shortages are limited so far, and our ability to pass on higher input costs is generally solid. As we told you before, pricing in Life Science — and this is an important point — is currently around the higher end of the historical 1% to 2% range, and we expect to be slightly above that range going into next year.

Belén Garijo

executive
#17

When it comes to Electronics, cost pressure on inputs is a bit more of a factor. We're actively managing supply chains, qualifying extra suppliers, and building up safety stocks — whatever it takes. In Electronics we also intend to keep the impact as small as possible by taking suitable pricing steps within the industry's overall framework. And last but not least, let me restate what we've said previously: cost discipline stays a very high priority throughout the Company, and it has grown even further amid the pandemic. We're watching inflationary and supply chain pressures very closely, and we think we're operating from strength in navigating this situation. Our gross margins are attractive, our market positions are strong, and our systems and processes are built to adapt flexibly to a fast-changing environment and to manage potential challenges effectively so that our profitability is protected. Turning to Slide 18, a quick ESG update. Over the past couple of months, we've been assessing our route to climate neutrality by 2040. We've been talking about which technologies, which processes and what investment might be needed to meet our targets. As a result, we recently signed a commitment letter from the science-based target initiatives, and we will submit the validation documents before this year ends.

Belén Garijo

executive
#18

By making this choice, we can make sure our approach matches what the most recent climate science has determined is required for us to meet our climate goals. We're confident the science-based target initiative will validate our plan and award us a certificate in Q2 2022. Now, let me move to the guidance. I'm on Slide Number 19. Given the strong quarterly results in Q3 and a favorable outlook for the rest of the year, we are once again lifting our full-year guidance. Specifically, we now anticipate Group net sales between €19.3 billion and €19.85 billion, EBITDA pre between €6 billion and €6.3 billion, and EPS pre between €8.5 and €9. At the midpoint, that means a 2% increase on sales, 6% on EBITDA pre, and 7% on EPS pre compared with the prior guidance. Part of the reason for this guidance upgrade is a better currency outlook, which now assumes headwinds of 1% to 2% on both sales and EBITDA pre, versus the 2% to 4% we assumed in our previous guidance. On organic performance, we have increased our target for organic sales growth from 12% to 14% up to 13% to 15%, and for organic EBITDA pre growth adjusted for the Biogen provision reversal from 21% to 25% up to 26% to 29%.

Belén Garijo

executive
#19

Moving to Slide 20 for a sector-by-sector outlook update. On organic performance, beginning with revenues, we've turned somewhat more positive on Life Science and, to some degree, on Electronics as well. Where earnings are concerned, we've nudged up our Healthcare outlook, though the primary factor is once again Life Science's operational performance. Regarding Life Science, note that this upgrade stems equally from core business developments and from COVID-related sales. Accordingly, we're revising our Life Science COVID sales guidance upward to more than €1.1 billion, versus at least €1 billion previously. That increase, in turn, reflects COVID-related sales in Process Solutions, which we now project at around €1 billion, compared with at least €900 million before. Finally, we're lifting our 2022 guidance for COVID-related sales in Process Solutions to around €900 million, up from at least €700 million in the prior guidance. The reason is greater visibility plus the inclusion of boosters for the broader population and pediatric vaccines. Now to my final slide of the day, one many of you know from our Capital Markets Day — it's simply a reminder that we remain confident about meeting our long-term commitments through 2025.

Belén Garijo

executive
#20

Our goal is to speed up even more and lift our standards across every activity we undertake. The objective for the medium term is quite straightforward — it comes down to 25 by 25. In other words, we intend to reach €25 billion in sales by 2025, while adding over €1 billion in organic sales each year all the way through 2025. That works out to an organic sales CAGR exceeding 6% at the Group level. Achieving it will come from a substantial increase in our investment, with an extremely sharp laser focus on the Big 3, which serve as our main growth engines. Q3 demonstrates the enormous potential of the Big 3, and over recent weeks we have advanced further, among other things by opening our new viral vector facility in Carlsbad and by completing Phase III enrollment for evobrutinib, as Marcus already mentioned. We feel confident about Merck's future prospects. We keep mobilizing the whole organization for efficient growth. We are strongly committed to building a culture driven by high impact. We stand ready to drive innovation powered by digital and data, and we are committed to thinking and acting sustainably. Our Company possesses everything required to become the global 21st century's science and technology pioneer.

Belén Garijo

executive
#21

That's not just something we aspire to — it's our ambition. Thank you very much for your attention. And now I'll be glad to hand things over to Constantin so we can begin the Q&A.

Constantin Fest

executive
#22

Thanks so much, Belén. So with that, we’re ready to begin the Q&A portion of the session. And so, Tracy, yes, please go ahead — let’s open up the Q&A. Thank you.

Operator

operator
#23

Thanks. We’ll take our first question from Richard Vosser at JPMorgan. Go right ahead.

Richard Vosser

analyst
#24

Thanks for taking my question. I'd like to ask about Life Sciences, please. Since we saw a slight margin decrease in Q3 due to higher costs, how should we view margins for Q4 and heading into 2022, considering this greater investment? And just to add to that, regarding COVID revenues in Research Solutions, how do you expect those to progress in 2022? I believe there's roughly €100 million in that. Thanks very much.

Matthias Heinzel

executive
#25

Yes. Thank you, Richard. This is Matthias speaking. I'll take both of your questions. First, regarding margin: we anticipate it will decline step by step as time goes on, starting from today's elevated figures, and we look for it to land at the halfway point between where we stood before COVID — when it sat in the 31% range — and today's much higher levels. Partly, that reflects an anticipated easing of COVID competition across the coming quarters. And, as you correctly pointed out, there are our ongoing business investments, be it CDMO or growing R&D spend. So my expectation is that it declines across the coming quarters. Clearly, much rides on how much COVID contributes down the road. On your second question, research did indeed receive a COVID contribution this year. As a rough figure, it comes to roughly €150 million, which forms part of the €1.1 billion that Belén referenced. We are already watching that shrink as COVID testing falls alongside rising vaccination rates, and we expect further decline as we move into 2022.

Richard Vosser

analyst
#26

I appreciate that.

Operator

operator
#27

Our next question comes from Matthew Winston at Credit Suisse. Please go ahead.

Matthew Winston

unknown
#28

Thanks a lot. My question picks up where Richard left off, and it's likewise about COVID's effect on Process Solutions in 2022. I believe there was a Bloomberg interview this morning in which you cited €900 million for 2022 in Process Solutions. Clearly, there's been a fair amount of investor worry throughout the market, Belén, regarding how antiviral small molecules could affect vaccine demand. So I'd be quite interested if you could give us some color on how you built up your assumptions for 2022 to arrive at that €900 million — in terms of boosters, pediatric and other drivers? Many thanks.

Belén Garijo

executive
#29

Thanks, Matthew. I'll keep this short, and then I'll have Matthias go a little deeper on the assumptions. Look, volatility in the market isn't going away, yet vaccines are going to stay central to how we tackle the COVID-19 pandemic. So, as I said in the introduction, our build assumes vaccines keep that role — boosters, and the broad population staying committed to using them. Matthias.

Matthias Heinzel

executive
#30

Yes, thank you. First off, I believe we're all glad to have one more option available in the fight against COVID. To address your question specifically, there are essentially three main angles I consider when thinking about how COVID might play out. Naturally, the first is primary vaccination. That hinges on the target vaccination coverage we're able to reach. There's still some distance to cover, I'd say, particularly when you look at areas beyond the mature regions. Second, the age groups — right, how far can we anticipate that going. I think we're seeing certain regions and countries now definitely including children as well. That's a determining factor, in a sense. And then, very importantly, the boosters. Here we're watching three things, roughly. What's the adoption rate going to be? That is, how many of those who received the initial vaccination will take the booster. The frequency — will it be every six, nine months. But one very significant aspect is the dosage. The dosage has been published by some of the M&A players, and the dosage is half the level of the primary vaccination round. So that's something we need to bear in mind when we consider COVID's impact next year.

Matthias Heinzel

executive
#31

Then naturally, the open question is whether a variant should or will emerge, and that would mean they’d need what I term the vaccine update—you’d have to develop a new prime vaccine. After that, as Belén mentioned, antivirals are of course available, with plenty of volatility. My view is that there are also 2 more angles to consider. Angle 1 involves the production availability of some of those antivirals, plus the cost side. So when you factor all of that in and look toward 2022, we think COVID and vaccination will remain the prime line of defense, so to speak, and we’ll still see a significant contribution. I laid out the levers for you, and clearly, how those levers play out will determine whether it lands in the range of the €900 million we gave.

Matthew Winston

unknown
#32

Thanks a lot.

Operator

operator
#33

Our next question comes from Peter Verdult at Citi. Please go ahead.

Peter Verdult

analyst
#34

Peter Verdult from Citi here. Apologies for that, Belén. I have one question and 1 point of clarification, if I may. Matthias, on the supply bottlenecks — I raised this last quarter and I realize you're putting serious effort into expanding capacity for new modalities. But when it comes to filtration and single use, will those supply constraints be sorted out in 2022? Then just a quick clarification: Marcus, I believe you mentioned evobrutinib data in the first quarter of 2023. From what I saw, the trial has only just wrapped up, and it involved a two-year fixed follow-up. So I just wanted to get clarity on the timing for the Evobrutinib Phase III?

Matthias Heinzel

executive
#35

Yes, Peter, I’ll take the first question. And there really is a great deal of effort underway across our teams to do what we refer to as debottlenecking. As you’ve noticed, we’ve had a sequential increase in Process Solutions, and much of that is due to the debottlenecking work we’ve completed. We’ve also said that, in addition to those efforts, we’ll bring new single-use capacity online — for instance, the first phase will come online in a couple of months, and we’ll expand further early next year. Broadly speaking, I’d expect capacity to remain constrained, so through the middle of next year this will continue. So I’d say that at least until mid of next year, we should still be in this kind of constrained situation. But everyone has been fully engaged in Denver a couple of weeks ago, the team is on it, and hard work is continuing so we can release every product we can from our lines.

Marcus Kuhnert

executive
#36

Peter, just a moment, and then I'll pass it to Peter Guenter. I did say we anticipate having the data in-house by Q4 2023, that's correct. But let me turn it over to Peter for further details.

Peter Guenter

executive
#37

Right. Well, I won't argue with you there, Marcus. Regarding the fourth quarter of 2023 and speaking broadly, we're certainly quite pleased that enrollment has been completed for over 2,000 patients across the pivotal Phase III trials, and we're eager to have that data in hand and then, naturally, move through a swift process to bring the product to market as quickly as we can after that.

Peter Verdult

analyst
#38

Appreciate the clarification. Thank you.

Operator

operator
#39

Our following question comes from Sachin Jain at Bank of America. Go right ahead.

Sachin Jain

analyst
#40

Thanks for taking my questions. I have just one on Life Science, following up on the earlier one. I'm wondering whether you could give some high-level comments on the underlying growth in Process Solutions and how we should think about it going into 2022. Should we think about an acceleration toward the back end of the year as CapEx comes through, or is the existing growth rate sustainable? And I wonder if you could try to address that relative to the trend year-to-date. So based on your commentary, it seems like roughly 10% underlying in the third quarter versus a mid-teens run rate for the full year? Thank you.

Matthias Heinzel

executive
#41

Yes. Hi Sachin, this is Matthias. Thanks. So on the whole, I mean, we feel very confident in the midterm guidance we gave for Process Solutions, which was in the low to mid-teens. And that assumed, if you will, kind of a fading of the COVID contribution over the years. So as we head into 2022, we are very confident about that. I think one factor is also that our order intake is still strong. The order book is still strong, and particularly the order intake for the base business has kept growing. So that gives us confidence about the peers growth as we go into 2022. And obviously, also when it comes to CapEx, I just mentioned the project in most time for single-use. We are accelerating as much as we can. We had announced additional projects. We have announced projects when it comes to our, which feed actually into (Ph). So we are pretty much accelerating as much as we can to get this new capacity online.

Sachin Jain

analyst
#42

Thanks.

Operator

operator
#43

Our next follow-up question comes from Matthew Weston at Credit Suisse. Go right ahead.

Matthew Weston

analyst
#44

Thanks. That came through faster than I anticipated. Belén, in your opening remarks you mentioned a temporary dip in Glucophage and linked it to China VBP. That would interest me a lot — a temporary dip suggests a recovery. So I'd be very interested in the timing as to when you expect that recovery? Was this a 3Q event or do we just need to see volumes build over the course of 2022 into 2023?

Belén Garijo

executive
#45

Matthew, I’ll have Peter walk you through the specifics, but if you look back at what we communicated previously and how we projected the GDP effect on Glucophage, it has played out precisely as we expected. That impact is temporary, it is clearly near a rebound, and maybe Peter can add more on how we view things at the local level in China.

Peter Guenter

executive
#46

Yes, absolutely. Thanks, Matthew, for that question. So as you may recall, Glucophage had its Q4 impact last year. That will annualize in the coming quarter. So we're quite confident that we're actually bottoming out right now, and you should see growth starting from Q4 onward. That said, it isn't just the mechanics of the prior quarter. It's also a great deal of hard work on the ground in China, working to maximize the opportunities for the brand beyond the core hospitals. So I mean retail, I mean county hospitals, and I mean primary care, community healthcare centers. So a lot of hard work sits behind this to make sure we leverage every single opportunity over the next couple of years to maximize Glucophage's potential. And then perhaps also to remind you that Glucophage in China is only part of the picture. We have really very interesting double-digit growth quarter after quarter in other regions of the world — think LatAm, think Middle East, think other APAC countries outside China. So all in all, I'm quite confident about seeing growth for Glucophage in the future.

Matthew Weston

analyst
#47

Thanks.

Operator

operator
#48

Moving on, our next question comes from James Quigley at Morgan Stanley. Go right ahead.

James Quigley

analyst
#49

Hey, thanks for taking my questions. So, just a quick one on Process Solutions. You obviously mentioned that you're investing for growth in the CDMO business as part of that. So could you give us a high-level overview of the split between revenues, or current revenues, across the CDMO services, tools and equipment, and then the other service businesses, and maybe a high-level overview of the growth rates you're seeing on those businesses?

Matthias Heinzel

executive
#50

Sure, and thanks for asking. At a broad level, our service business generally accounts for under 10% to 15% of the whole Process Solution business. That figure takes in our current CDMO operations. As you're aware, we already run an existing CDO business in the mass area and in high-API, and it also covers the testing service we offer under the BioAlliance name. So when I put that sort of service segment together, it comes to under 50% of the Process Solutions business we have right now.

James Quigley

analyst
#51

I appreciate that.

Operator

operator
#52

Our next question comes from Gary Steventon at Exane BNP Paribas. Please go ahead.

Gary Steventon

analyst
#53

Thanks a lot for taking my question. I just have a quick one about the semis business, please. You said the strong growth in the quarter came from both materials and DS&S offerings, and you expect that capable phasing in DS&S to carry on into the first half of next year. That seems to suggest the strong Q3 performance could be extrapolated at least across the next three quarters or so. So I'd be interested in your thoughts on how durable that strong Q3 number is and on the market trends you're seeing that support it. Thank you.

Kai Beckmann

executive
#54

Yes, Gary, it's Kai here. Thank you for that question. So regarding the split, if you examine our Delivery and Services business, that has — and naturally, there's a phasing, as it was described, earlier. That portion will run through the end of next year. And naturally, we'll then gain from positive comps across the following three quarters in the Delivery Systems business. And just to frame that, this is an extra project business sitting on top of a very strong base business. So it isn't bumpy, as someone mentioned somewhere. This sits on top of a very strong base business, an amazing project over the coming couple of quarters through the end of next year, with good comps across the next three quarters. The Materials business is very strong as well. So it performed precisely in line with what we shared at our Capital Market Day and contributes a great deal to that growth too. So it's a major portion of delivering a strong Q3 this year.

Operator

operator
#55

Our next question comes from Falko Friedrichs at Deutsche Bank. Go ahead, please.

Falko Friedrichs

analyst
#56

Thanks so much. Good afternoon. My question concerns Mavenclad, if you don't mind. Can you tell us if the rise in COVID cases across a number of regions is having any effect at all on the high-efficacy market where Mavenclad is concerned, and on Mavenclad as well, could you give us a quick update on any shifts in market share for the drug? And finally, apologies, also on Mavenclad, I believe I raised this on the last call, that vaccine-related data you showed us a few quarters back — are you seeing that working in your favor now? Thank you.

Marcus Kuhnert

executive
#57

Yes. Thanks, Falko, for those questions. I'll take them one at a time. First, as you've noticed, we posted an interesting growth rate. Once you strip out the one-offs, sequentially quarter-to-quarter we're up 20%, which I'd call solid performance. Yet, as you correctly note, market volume dynamics do matter significantly to us moving forward. And regarding returning year two patients, we feel quite confident. When it comes to new patients, of course, the dynamic market volume really serves as the leading indicator. You may have heard, for instance, Roche mention on their recent Q3 earnings call that the market remains dynamic. Frankly, we're seeing the same thing now since summer's end. In certain markets, notably the U.S., the COVID-19 delta wave is a topic. I don't have a crystal ball, but I'd say because of that market phenomenon, we could see considerable volatility across the coming quarters for that reason. So to answer your question: yes, of course, lingering COVID-19 concerns directly affect the overall market's size. On market shares — and this actually ties a bit to your third question about whether our vaccination story is getting traction.

Marcus Kuhnert

executive
#58

So yes, even with the U.S. market being quite crowded — partly because of launches from other players — we're keeping our share there with Mavenclad. Meanwhile, across the Atlantic, in quite a few European countries, we're actually picking up share. So from a competitive angle as well, we're pretty pleased with how Mavenclad is progressing. The key point, though, is that this is a high-efficacy market and, once again, it's somewhat subdued in the U.S., which could bring some ups and downs going forward.

Falko Friedrichs

analyst
#59

Alright, thanks.

Operator

operator
#60

Our following question comes from Daniel Wendorff at ODDO. The line is yours.

Daniel Wendorff

analyst
#61

Yes, good afternoon, and thank you for taking my question. There are actually two small ones, both about Life Science. On the first, when you mentioned strong order growth in Q3, could you potentially say whether some positive effect comes from preordering, given the tight supply in the market, or perhaps an inventory buildup effect in there? And also a simple one, maybe as a follow-up to the last questions: are the new upcoming treatment options for COVID-19 also an opportunity for your Life Science business, so that you can supply production for these new corona pills as well?

Matthias Heinzel

executive
#62

Yes. Thank you, Daniel. I’ll address your first question. Our order intake is, in fact, still rising at a strong pace, and so is the order book. That said, lead times do remain quite lengthy, I believe, throughout the industry. Whether customers are now placing orders sooner is very hard to predict, and it is difficult to quantify. Overall, I’d say we feel very positive about this growth in order intake, once again also in relation to the base business. I think your question also suggested there might be an inventory buildup in the chain. From all our conversations with customers, we don’t see that. I mean, we are really still very much constrained from a supplier standpoint. And because of that, we still have those long lead times, which we need to reduce. On your second question, we do not, in reality, have a participation in those antiviral medications as part of the treatment for Life Science.

Daniel Wendorff

analyst
#63

Thank you.

Operator

operator
#64

We'll move on to the next question now, coming from Simon Baker at Redburn. Please go ahead.

Simon Baker

analyst
#65

I appreciate you taking my question. Turning back to Semiconductor Solutions, the year-on-year growth is really strong. Growth on a sequential basis for the quarter was quite robust. So I'm just curious whether you could update us on capacity expansion within the semis industry. Is that beginning to materialize? And is the visibility you have, along with your outlook regarding capacity expansion, in line with expectations, or are you observing an acceleration in new capacity being introduced within semis? Thank you very much.

Marcus Kuhnert

executive
#66

Absolutely, Simon, I’ll handle that question. So there’s the usual annual capacity increase, same as always. That hasn’t changed in any major way. So these are coming online. But what you’ve heard about, of course, during this year is the substantial additional investments, and we won’t see those coming on stream anytime before 2023. I think none of those investments will be active before then. So that means we see the normal capacity increase as in the past. Does that answer your question, Simon?

Simon Baker

analyst
#67

Yes. Thanks very much.

Operator

operator
#68

Our next question comes from Wimal Kapadia at Bernstein. Please go ahead.

Wimal Kapadia

analyst
#69

Thanks a lot for taking my question. This is Wimal Kapadia from Bernstein. I think this is another one for Kai. On Electronics margins, you posted a pretty strong margin this quarter. Could you give us some additional context on margins, particularly for semi and display? Is semis mostly what's delivering the leverage, or is it now stability plus growth in display margin since OLED is division? I'm just trying to figure out what's driving the strong margins and whether this strength should be assumed going forward, especially given some of the earlier remarks on inflation. Thank you.

Kai Beckmann

executive
#70

Thank you, Wimal, for raising that question, since the margin picture breaks down like this. There are supportive elements, including our Bright Future efficiency program, which is producing results, along with the synergies we are realizing and the integration benefits — those are positive contributors. Additional favorable elements include the mix effect from the faster-growing semi materials business, which we certainly need to factor in too. On the downside, higher costs have been with us for a number of quarters already. That is a persistent drag we observe, and more recently rising raw material costs have begun to take effect, which should give you at least some sense of the outlook, and we are trying to recover as much of that as we can. Still, that weighs on our margins on the negative side. So Q3 is a quarter that has been affected more on the positive side, but these factors, since the raw material developments are very recent developments.

Wimal Kapadia

analyst
#71

Thanks — that's great.

Constantin Fest

executive
#72

I believe there's room for one additional question, please.

Operator

operator
#73

Our final question today comes from Florent Cespedes at Societe General. Please go ahead.

Florent Cespedes

analyst
#74

Good afternoon, everyone. This is Florent Cespedes calling from Societe General. I have a quick question about Pharma. Would you be able to share some additional detail regarding how the fertility business performed, and in particular what is happening in the U.S., where things seemed a little soft this quarter? Thank you.

Marcus Kuhnert

executive
#75

Yes, Florent, thanks for asking. As a matter of fact, what you've observed is that our fertility business keeps expanding at a quite robust 7% rate quarter-over-quarter. There's a single exception, and that's the U.S., which is approximately flat. The only reason for that is the comparatively tough comps in Q3 of last year, since, as you'll probably recall, Q2 of last year was, naturally, extremely weak, and a sort of rebound occurred in Q3, which left the comps somewhat tricky for the current quarter. Still, honestly, looking ahead, I can confidently steer you toward mid-single-digit growth at a constant rate for this business.

Florent Cespedes

analyst
#76

Alright, thanks a lot. That's quite clear — thank you.

Constantin Fest

executive
#77

Appreciate it a lot. With that, I'd like to pass things over to Belén for some closing remarks.

Belén Garijo

executive
#78

Okay, very briefly — thank you, Constantin, and above all, thanks to all of you for your questions and for the ongoing interest you've shown in Merck. Without question, Q3 was a very strong quarter, yet another illustration of the tremendous potential that our unique portfolio holds. And at this point we're sharply focused on driving toward year-end so we can deliver on the commitments we've put forward as part of our guidance upgrade. I look forward to continuing the conversations with many of you during our Road Shows over the coming weeks. And stay safe and stay well. Talk to you soon. Bye-bye.

Operator

operator
#79

Thank you for joining us, everyone. That brings this call to a close. You can now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.